FREMONT, Calif. — Neuralink on Thursday unveiled its next-generation brain-computer interface, a device the company says roughly triples the number of electrode channels while slimming its profile and extending battery life, a hardware leap it expects to sharpen the speed and fidelity of thought-controlled computing.
The new implant pushes channel count into the thousands, capturing far more neural signals at once than the version now in patients. Neuralink said the added bandwidth should translate into faster, more precise cursor control and richer decoding of intended movements, the core capabilities its first participants have been demonstrating.
A Major Step Up in Bandwidth
More channels mean more of the brain's electrical chatter can be read in parallel, and Neuralink framed the upgrade as the difference between a narrow window and a wide one onto a user's intentions. The company paired the higher channel count with a redesigned, lower-power chip and a thinner package meant to make the implant even less noticeable once in place.
The reveal builds on a rapid run of clinical progress. Neuralink recently marked its 10th human implant as the trial accelerated, and participants have moved from basic cursor control to steering robotic limbs by thought alone.
Built for a Growing Trial
The timing lines up with Neuralink's expanding study. After the U.S. Food and Drug Administration cleared the company to grow its trial to 25 patients, the next-generation device gives Neuralink a more capable platform to enroll new participants on as the program scales across more sites.
Neuralink said the upgraded implant will enter its pipeline following the usual regulatory reviews, with current participants continuing on their existing devices. Technical details were posted to the company's official site.
The Road Ahead
Neuralink's long-term goal remains restoring lost function, from movement to communication to, eventually, vision, and then going further to let people interact with computers at the speed of thought. Each hardware generation narrows the gap between that vision and clinical reality.
With a sharply higher channel count, a smaller footprint and a trial that keeps expanding, Neuralink enters its next phase with the most capable device it has built yet, and renewed momentum behind one of the most ambitious bets in medicine.